Defence Therapeutics (TSE:DTC)
:DTC
Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.44 - C$0.93
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$43.96M
Enterprise ValueC$31.89M
Total Cash (Recent Filing)C$2.95M
Total Debt (Recent Filing)C$1.56M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformDefence Therapeutics owns the Accum® intracellular delivery platform, a durable technical moat that enhances biologic drug potency and delivery. A reusable platform across ADCs and immunotherapies can drive partnerships, licensing, and sustained R&D leverage beyond any single program.
Pipeline BreadthR&D efforts across oncology and infectious disease lower single-program binary risk and align with structural industry demand for biologics and ADCs. Multiple indication focus increases odds of a value-creating collaboration or milestone, supporting durable program optionality over months.
Improving Loss Trend & EquityA material narrowing of net losses year-on-year and a return to positive equity in the latest TTM indicate improving cost control and a stronger solvency position. These durable improvements extend runway and reduce near-term restructuring risk if sustained through upcoming quarters.
Bears Say
No Commercial RevenueThe company remains pre-revenue, with no product sales to support operations. Long-term value depends entirely on R&D outcomes, external funding, or partner deals; absence of commercial cash flow increases execution and financing risk over the next several months.
Persistent Cash BurnNegative operating cash flow and declining free cash flow (~-$3.7M FCF TTM) show ongoing cash consumption. This structural cash burn necessitates recurring capital raises or partnerships, which can dilute shareholders and constrain strategic choices if not addressed.
Balance-sheet VolatilityHistoric swings to negative equity and the presence of meaningful debt limit financial flexibility. Volatile balance-sheet metrics weaken borrowing capacity and heighten dilution risk if losses continue, creating a structural financing vulnerability over the medium term.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.43 and its highest was C$0.93 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$43.96M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 144 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.05.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---